Literature DB >> 35737015

[Postoperative outcomes and survival rates after aseptic revision total hip arthroplasty : What can patients expect from revision surgery?]

Manuela Hoffmann1, Johannes C Reichert1, Anastasia Rakow1, Janosch Schoon1, Georgi I Wassilew2.   

Abstract

BACKGROUND: In 2020, more than 14,000 aseptic revision procedures for total hip arthroplasty (THA) were registered in Germany. Patient expectations of revision hip arthroplasty are not substantially different from expectations of primary hip replacement. OUTCOME: However, revision surgery is associated with increased complication rates and a higher proportion of dissatisfied patients. In particular, poorer postoperative function and mobility as well as increased pain levels following revision THA have been described compared to the outcome after primary THA. Quality of life and return-to-work can also be impaired. SURVIVAL RATE: Implant survival is influenced by age, BMI, and comorbidities of the patients, but also by the size and complexity of bone defects, the extent of periprosthetic soft tissue compromise and the choice of revision implant(s). In addition, the number of previous revision surgeries inversely correlates with the survival rates. Previous revisions have been shown to be associated with increased risks of aseptic loosening, instability and periprosthetic infection.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Postoperative complications; Prosthesis loosening; Revision, joint; Survival rate; Total hip replacement

Year:  2022        PMID: 35737015     DOI: 10.1007/s00132-022-04274-1

Source DB:  PubMed          Journal:  Orthopadie (Heidelb)        ISSN: 2731-7145


  57 in total

Review 1.  The operation of the century: total hip replacement.

Authors:  Ian D Learmonth; Claire Young; Cecil Rorabeck
Journal:  Lancet       Date:  2007-10-27       Impact factor: 79.321

2.  Total joint arthroplasty in younger patients: heading for trouble?

Authors:  B Willem Schreurs; Gerjon Hannink
Journal:  Lancet       Date:  2017-02-14       Impact factor: 79.321

3.  Postoperative complication rates in the "super-obese" hip and knee arthroplasty population.

Authors:  Ran Schwarzkopf; Sean L Thompson; Sean J Adwar; Victoria Liublinska; James D Slover
Journal:  J Arthroplasty       Date:  2011-06-14       Impact factor: 4.757

Review 4.  Hip arthroplasty.

Authors:  Robert Pivec; Aaron J Johnson; Simon C Mears; Michael A Mont
Journal:  Lancet       Date:  2012-09-26       Impact factor: 79.321

5.  Obesity and perioperative morbidity in total hip and total knee arthroplasty patients.

Authors:  Robert S Namba; Liz Paxton; Donald C Fithian; Mary Lou Stone
Journal:  J Arthroplasty       Date:  2005-10       Impact factor: 4.757

6.  Long-term outcomes of total hip arthroplasty in patients younger than 55 years: a systematic review of the contemporary literature

Authors:  Xin Yu Mei; Ying Jia Gong; Oleg Safir; Allan Gross; Paul Kuzyk
Journal:  Can J Surg       Date:  2019-08-01       Impact factor: 2.089

7.  Does Activity Level After Primary Total Hip Arthroplasty Affect Aseptic Survival?

Authors:  David A Crawford; Joanne B Adams; Gerald R Hobbs; Michael J Morris; Keith R Berend; Adolph V Lombardi
Journal:  Arthroplast Today       Date:  2021-08-23

8.  Future young patient demand for primary and revision joint replacement: national projections from 2010 to 2030.

Authors:  Steven M Kurtz; Edmund Lau; Kevin Ong; Ke Zhao; Michael Kelly; Kevin J Bozic
Journal:  Clin Orthop Relat Res       Date:  2009-04-10       Impact factor: 4.176

9.  Are younger patients undergoing THA appropriately characterized as active?

Authors:  James A Keeney; Ryan M Nunley; Geneva R Baca; John C Clohisy
Journal:  Clin Orthop Relat Res       Date:  2014-09-23       Impact factor: 4.176

10.  Predictors of Outcome After Primary Total Joint Replacement.

Authors:  Markus Weber; Benjamin Craiovan; Michael L Woerner; Timo Schwarz; Joachim Grifka; Tobias F Renkawitz
Journal:  J Arthroplasty       Date:  2017-09-07       Impact factor: 4.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.